PLUS THERAPEUTICS, INC. — Director's Dealing 2018

Jul 27, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: CYTORI THERAPEUTICS, INC. (CTYX)
CIK: 0001095981
Period of Report: 2018-07-25

Reporting Person: HEDRICK MARC H (President and CEO)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-07-25	Subscription Rights (Right to Buy)	$1000.00	X	35	Disposed	2018-07-20	See Footnote ()	Direct
2018-07-25	Series C Preferred Stock	$0.7986	X	35	Acquired		Common Stock (43827)	Direct
2018-07-25	Warrants (Right to Buy)	$0.7986	X	36750	Acquired	2021-01-25	Common Stock (36750)	Direct

Footnotes

F1: The preferred stock and the warrants reported on this Form 4 were acquired pursuant to the exercise of subscription rights previously distributed by Cytori Therapeutics, Inc. (the "Company") to all holders of the Company's common stock and Series B Preferred Stock on June 26, 2018. The subscription rights entitled each recipient to purchase units ("Units"). Each Unit consists of one share of the Company's Series C Preferred stock (convertible into 1,253 of the Company's common stock) and 1,050 warrants, with each warrant representing the right to purchase one share of the Company's common stock. The purchase price for each Unit was $1,000.

F2: The Series C Preferred Stock has no expiration date.

F3: Each warrant entitles the holder to purchase one share of the Company's common stock at an exercise price of $0.7986 through January 25, 2021.